Principles of nanoparticle design for overcoming biological barriers to drug delivery
TLDR
By successively addressing each of the biological barriers that a particle encounters upon intravenous administration, innovative design features can be rationally incorporated that will create a new generation of nanotherapeutics, realizing a paradigmatic shift in nanoparticle-based drug delivery.Abstract:
Biological barriers to drug transport prevent successful accumulation of nanotherapeutics specifically at diseased sites, limiting efficacious responses in disease processes ranging from cancer to inflammation. Although substantial research efforts have aimed to incorporate multiple functionalities and moieties within the overall nanoparticle design, many of these strategies fail to adequately address these barriers. Obstacles, such as nonspecific distribution and inadequate accumulation of therapeutics, remain formidable challenges to drug developers. A reimagining of conventional nanoparticles is needed to successfully negotiate these impediments to drug delivery. Site-specific delivery of therapeutics will remain a distant reality unless nanocarrier design takes into account the majority, if not all, of the biological barriers that a particle encounters upon intravenous administration. By successively addressing each of these barriers, innovative design features can be rationally incorporated that will create a new generation of nanotherapeutics, realizing a paradigmatic shift in nanoparticle-based drug delivery.read more
Citations
More filters
Journal ArticleDOI
Nano based drug delivery systems: recent developments and future prospects
Jayanta Kumar Patra,Gitishree Das,Leonardo Fernandes Fraceto,Leonardo Fernandes Fraceto,Estefania Vangelie Ramos Campos,Estefania Vangelie Ramos Campos,Maria del Pilar Rodriguez-Torres,Laura Susana Acosta-Torres,Luis A. Diaz-Torres,Renato Grillo,Mallappa Kumara Swamy,Shivesh Sharma,Solomon Habtemariam,Han-Seung Shin +13 more
TL;DR: An updated summary of recent advances in the field of nanomedicines and nano based drug delivery systems through comprehensive scrutiny of the discovery and application of nanomaterials in improving both the efficacy of novel and old drugs and selective diagnosis through disease marker molecules is presented.
Journal ArticleDOI
DLS and zeta potential - What they are and what they are not?
TL;DR: This review tries to address the issue while providing the fundamental principles of these techniques, summarizing the core mathematical principles and offering practical guidelines on tackling commonly encountered problems while running DLS and ZP measurements.
Journal ArticleDOI
Engineering precision nanoparticles for drug delivery
Michael J. Mitchell,Margaret M. Billingsley,Rebecca M Haley,Marissa E. Wechsler,Nicholas A. Peppas,Robert Langer +5 more
TL;DR: Advances in nanoparticle design that overcome heterogeneous barriers to delivery are discussed, arguing that intelligent nanoparticles design can improve efficacy in general delivery applications while enabling tailored designs for precision applications, thereby ultimately improving patient outcome overall.
Journal ArticleDOI
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date.
Daniel Bobo,Kye J. Robinson,Jiaul Islam,Jiaul Islam,Kristofer J. Thurecht,Simon R. Corrie,Simon R. Corrie +6 more
TL;DR: An up to date snapshot of nanomedicines either currently approved by the US FDA, or in the FDA clinical trials process is provided, and there is a trend towards the development of more complex materials comprising micelles, protein-based NPs, and also the emergence of a variety of inorganic and metallic particles in clinical trials.
Journal ArticleDOI
Near-infrared fluorophores for biomedical imaging
TL;DR: This Review covers recent progress on near-infrared fluorescence imaging for preclinical animal studies and clinical diagnostics and interventions.
References
More filters
Journal Article
A New Concept for Macromolecular Therapeutics in Cancer Chemotherapy: Mechanism of Tumoritropic Accumulation of Proteins and the Antitumor Agent Smancs
Yasuhiro Matsumura,Hiroshi Maeda +1 more
TL;DR: It is speculated that the tumoritropic accumulation of smancs and other proteins resulted because of the hypervasculature, an enhanced permeability to even macromolecules, and little recovery through either blood vessels or lymphatic vessels in tumors of tumor-bearing mice.
Journal ArticleDOI
Understanding biophysicochemical interactions at the nano–bio interface
Andre E. Nel,Lutz Mädler,Darrell Velegol,Tian Xia,Eric M.V. Hoek,Ponisseril Somasundaran,Fred Klaessig,Vince Castranova,Mike Thompson +8 more
TL;DR: Probing the various interfaces of nanoparticle/biological interfaces allows the development of predictive relationships between structure and activity that are determined by nanomaterial properties such as size, shape, surface chemistry, roughness and surface coatings.
Journal ArticleDOI
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review.
TL;DR: The basic characteristics of the EPR effect, particularly the factors involved, are described, as well as its modulation for improving delivery of macromolecular drugs to the tumor.
Journal ArticleDOI
Multidrug resistance in cancer: role of ATP–dependent transporters
TL;DR: The ability to predict and circumvent drug resistance is likely to improve chemotherapy, and it has become apparent that resistance exists against every effective drug, even the authors' newest agents.
Journal ArticleDOI
Stimuli-responsive nanocarriers for drug delivery
TL;DR: Recent advances in the design of nanoscale stimuli-responsive systems that are able to control drug biodistribution in response to specific stimuli, either exogenous (variations in temperature, magnetic field, ultrasound intensity, light or electric pulses) or endogenous (changes in pH, enzyme concentration or redox gradients).